Developing non-invasive cancer detection technologies to improve the lives of patients worldwide.

Part of exec team to shape strategy and decisions to navigate data read-out, value inflection, and cash burn. Led or co-led/supported the below transactions :1. M&A by Gilead for $4.9B all-cash, as a strategic investment in immuno-oncology2. Global co-development and co-commercialization term sheets for magrolimab, an innate immune checkpoint inhibitor3. Regional partnership with Ono for Japan territory ($16M UF, $120M M/S, and royalties)4. Research and clinical collaborations with gene therapy companies (BLUE and RCKT)5. Royalty monetization for future royalties of magrolimab as a strategic non-dilutive financing option6. Equity financing through two secondary raises to fund pipeline; form a syndicate, define banker economics, list target investors, launch offering and determine allocations7. Grants from LLS and CIRM for non-dilutive milestone funding of clinical studies 8. Academic IP license and collaboration with Stanford OTL and NIH9. Evaluate in-license of complementary pipeline products focused on enhancing eat me signals or blocking don’t eat me signals or activating macrophagesTherapy Area focus: immuno-oncology, gene therapy

Shape strategy and build BD function from scratch. Execute 4 deals in 2 yrs. Hands-on and collaborative. 1) Regional deal (O/L) in China (upfront $30M, $230M milestones, tiered royalty)2) Monetize (O/L) pre-clinical asset for non-dilutive funding (UF $25M, $325M M/S, royalty)3) Second source manufacturing agreement for DP 4) Strengthen IP portfolio and in-license new patentsExperience with contracting/negotiation, deal models, and diligence. Deal closer and relationship builder.Therapy Area focus: Aesthetics, CNS, Biosimilars

Experience in buy and sell side BD transactions, and alliance management, commercial development and new product planning. Shape corporate strategy and portfolio management.1. PFE acquisition ($5.2B all cash)2. Amended NVS/Sandoz US commercial distribution agreement for Kerydin ($40M upfront, $25M milestone, 50% gross profit split, $65M minimum payments).3. Managed Kerydin alliance and quarterly JSC meetings. Co-lead for PFE transition (pre-close data room and queries, post close integration activities).TA focus: Dermatology/Aesthetics, Infectious Diseases, Inflammation/Immunology

1. Business Development and Commercial Assessment2. Commercial Strategy for ex-US (EU, LatAm, Canada, APAC, MENA)3. Global Reimbursement, Pricing, and Access4. New Product PlanningTA focus: Orphan/Rare (Cystic Fibrosis), CNS (pshyciatric disorders), GI, MS, Oncology, DermatologyJoined Forest Pharmaceutical (which became Allergan after acquisition)

Global Brand Marketing, Launch Planning, Early Commercialization, Portfolio Management & StrategyTA focus: Infectious Diseases, Vaccines, CNS-Neurological (Alzheimer's, Parkinson's), Pain Joined MedImmune which is now part of AstraZeneca.

1. Business and Commercial Analysis2. Global Product StrategyTA focus: CV, Diabetes, Obesity

Management Consultant to Pharmaceutical/Biotech and Medical Device companies (Fortune 100, Small and Midsize)Growth Strategy, Operational Excellence, R&D Productivity, Commercialization, and BD&LPromoted from Consultant to Manager to PrincipalJoined PRTM which was acquired by PwC